The California Institute for Regenerative Medicine (CIRM) and the UK Regenerative Medicine Platform (UKRMP) have similar objectives, but their histories, funding mechanisms and governance could hardly be more different. Here, we compare the two programmes and explore their impact in translating stem cell research into clinical applications.
Scientists cherish their autonomy, mobility and international perspective. We are just as likely to know what is happening in a colleague's lab in a different country as to know the latest data from a lab just across the hallway. One thing that is heavily influenced by location, however, is our source of funding. This in turn depends on the political climate of the country in which we work, as exemplified by research on stem cells. million a year. In this piece we examine the impact of these two initiatives on stem cell research and translation. While CIRM has invested heavily in basic biology, in 2008, the agency awarded grants to encourage scientists to form 'disease teams' to develop pathways for translating fundamental research into therapies, and assigned project managers to focus on specific deliverables. This led to more substantial investment, from 2009, in translational projects, with a similar objective to that of the UKRMP to move stem cell research closer to application. Some potential therapies involve cell transplantation;
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Spending the money
others involve biologics such as antibodies and viral vectors. Drug discovery and in vitro disease modelling are also funded.
Notably, CIRM has awarded substantial funds in the form of loans to the commercial sector. In some cases this has been a roller coaster ride. neatly circumvents a problem facing the UK stem cell bank, which is that the commercial sector is uncomfortable with others being able to access the same cell stocks because of the possibility of 'contamination' of their product through academic results that may concern regulators. Compared to activity at CIRM, the UKRMP has distributed its funds in two major tranches. 
Are CIRM and UKRMP a success?
From a broad perspective, new sources of research funding are always welcome.
However, it is human nature that scientists in different disciplines become annoyed (and vocal) when they feel that money for new initiatives comes at the expense of their own research. CIRM funding is arguably new money that would not otherwise have gone into research and it seems unlikely that any other state would be able to raise an equivalent amount in the same way. In contrast, the UKRMP is seen as a potential model for government-backed initiatives in other areas, and indeed the MRC is providing £12m to support the creation of the Dementias Platform UK (DPUK) (https://www.mrc.ac.uk/research/facilities/dementias-platform-uk/).
There is no doubt that stem cell research in California has been boosted at many different levels by CIRM. The Agency has not been without its problems, however, including sudden changes in leadership, accusations of conflict of interest and slow decision-making. To address these CIRM invited the Institute of Medicine of the US National Academies (IOM) to review its operations, resulting in a report, published in December 2012, that suggested improvements in CIRM governance structure, scientific program, and policies (http//www.iom.edu/cirm). Importantly, although many of their suggestions were taken into consideration, some of their proposals were inconsistent with standard policies followed by other oversight committees including at NIH institutions. For example, the IOM report considered an oversight board that included university representatives and disease advocates to be a conflict of interest, even through they recused themselves from voting on grants from their own institution, yet all NIH councils also have university and diseases advocacy group individuals as members. Nonetheless, Alan Trounson, then President of CIRM, developed an international Scientific Advisory Board as a result of the IOM report, which has not been used by his successor.
As a government funded initiative that does not directly award grants or loans to industry, UKRMP has been largely immune from the problems that have affected CIRM. However, it is probably fair to say that initially Hub researchers were unused to the milestone-driven approach of the programme board, and that the system for distributing funds between universities within a Hub makes it hard to respond to shifting priorities.
In addition to research funding there have tangible financial benefits to California in terms of job creation (for example in construction) and tax revenue; recipients of CIRM grants must 'buy California first' when it comes to grant expenditure. CIRM supporters point to the growth 6 in Californian Biotech since CIRM was created. However, there has been a similar growth in the Boston area, which has not received the same injection of cash for regenerative medicine. It seems likely that Biotech companies favour close proximity to centres of research excellence and in that sense CIRM has had a positive effect The UKRMP is not under the same pressure as CIRM, partly because of its provenance and partly because it is a younger initiative. Nevertheless, there are heartening signs that UK researchers are becoming more active in cell therapies and the Cell Therapy Catapult has documented a steady rise in cell therapy trials in the UK since 2012, with 51 trials now ongoing. Given that a major driver for the creation of CIRM was the potential of treatments based on human pluripotent stem cells it is interesting that most of the cell therapies currently in the clinic, both in the US and in the UK are based on somatic cells, andat least in the UKon autologous cells (https://ct.catapult.org.uk/clinical-trials-database). Thus, ironically, most current CIRM-funded trials would also have been eligible for federal funding.
What next?
Devotees of British comedy will recognise the Monty Python quote '"Nobody expects the Spanish Inquisition...because our chief weapon is surprise!" Over the years veterans of stem cell research (including the authors) have learned to expect the unexpected. In conclusion, both CIRM and UKRMP have similar goals but different routes (and funding) to achieving them. Connecting people to work together to move regenerative medicine into the clinic is an over-arching objective and one that, we hope, will benefit patients regardless of where they live.
Disclosures: ILW is a co-author of Proposition 71, co-founder of Stem Cells, Inc, grantee of CIRM, and inventor of patents held by Stanford University in the areas of CIRM funding. He has also recently co-founded Forty Seven, Inc, a company taking CD47 related therapeutic antibodies through clinical trials. FMW receives UKRMP funding and was involved in the consultation process that influenced creation of UKRMP. She was also a member of the CIRM scientific advisory board created in response to the IOM review and is a non-executive director of the Cell Therapy Catapult. A list of all the web links will appear here
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